30 thermal cycles each of one minute at 94°C, 30 seconds at 54°C, one minute at 72°C; finally there was a 10 minute incubation at 72°C. For the primers for RYR1, PCRs for flanking markers were performed as for the RYR1 repeat except annealing temperatures were as follows: D19S191 45°C, D19S47 57°C. The resultant products were analysed by electrophoresis on a 6% denaturing polyacrylamide gel at 60 W for three hours. The gel was then fixed, dried, and exposed to fast, blue x ray film (Genetic Research Instrumentation) for 12 to 36 hours. Families uninformative for any of the markers were typed with further closely flanking markers on 1 9q1 3 (data not shown).
Two point lod scores were obtained using LINKAGE v 5.04, assuming gene penetrances of 0.98 and 0.98 for the normal and susceptibility alleles respectively, and a disease gene frequency of 1:5000 (these are the figures agreed by the Genetics Section of the European Malignant Hyperthermia Group). Multipoint lod scores and the HOMOG v 3.3 analyses'3 were performed at the MRC Human Genome Mapping Project resource centre, Cambridge, UK. Multipoint lod scores were generated using LINKAGE with LINKMAP. The disease locus was placed within a fixed map of three markers, D19S191, WUT1.9, and RYR1. The intermarker 0 values used were as follows: D19S191, 0=0.021; W IT1.9, 0=0.002; RYR1, 0=0. These values were calculated on the basis of physical mapping data and assuming 1 Mb=l cM, 1cM=0 of 0.01. As the genetic distances were so small, intermarker values of 0 could not be accurately computed using the data set discussed here.
Results
The results from 20 families, incorporating 250 phenotyped and 249 genotyped subjects, were analysed. The segregation of the chromosome 19ql3.1-13.2 markers with MH susceptibility is summarised in table 1, along with the multipoint lod scores and the results of the HOMOG analyses.
In nine of the families, segregation was consistent with linkage of MH susceptibility to RYR1, whereas in three families there were at least two recombinants, strongly suggestive of MH not being caused by RYR1, although in only one family did the lod score reach -2.0. It was especially in the remaining families, where segregation was incomplete owing to a single recombinant subject, that we envisaged that the likelihood of linkage to RYRI generated by the HOMOG analyses would be useful.
Discussion
Published linkage studies of malignant hyperthermia have been carried out on remarkably few large, well characterised families. This is mainly because of the nature of the phenotyping process, which involves open muscle biopsy carried out at a diagnostic centre often a long distance from the patient's home. These studies have, however, enabled the identification of the MHS 1 locus RYRI and also indicated that there is genetic heterogeneity underlying malignant hyperthermia. Levitt et al'0 presented three families where linkage to 19q13.1-q13.2 was excluded, but the results presented in that paper are difficult to evaluate as there are no means to appraise the phenotypes critically (absence of muscle contracture data). A report by Deufel et all" suggested that two Central European families also showed no linkage between malignant hyperthermia susceptibility and the 19q13.1 region. Similarly, Fagerlund et al"2 described recombinants between RYR1 and malignant hyperthermia susceptibility in two out of three Swedish families segregating informatively at the RYR1 locus. The presence of genetic heterogeneity in MH dictates that great caution be exercised when combining data from several small families.20 This could be why the report of linkage to chromosome 1 7q by Levitt et al' has yet to be substantiated. 22 23 Confirmation of genetic heterogeneity has been provided by the results of a genomic search that identified a high probability of linkage between MH susceptibility and chromosome 3q,24 and a fur-ther gene on chromosome lq.25 A further linkage region containing the gene for the a2/6 subunit of the skeletal muscle dihydropyridine calcium channel complex on chromosome 7q has also been reported. 26 While most authorities agree that genetic heterogeneity does exist, the proportion of families linked to RYR1 has not been determined. This again is probably the result of the difficulty in obtaining well characterised MH pedigrees. Such an estimate is important because it would give an indication of the proportion of families in which the diagnosis of MH could be made using the flanking DNA marker approach of Healy et al. 9 It would also provide the likelihood of finding a mutation in RYR1 of individual MH susceptible patients in whose family there were insufficient members to use a linkage approach. In this context it is interesting to note that the RYR1 mutations so far reported have been found in only about 10-15% of MH subjects screened.27 In addition, a number of families have now been recorded in which the MH status as determined by the IVCT does not correlate with the RYR1 mutation results. 28 29 The patient resource of the UK MH Investigation Unit, with more than 3500 people from over 500 families phenotyped by contracture testing, is the largest of its kind in the world. From these families we have selected 20 pedigrees with a structure and size potentially capable of providing informative linkage data. Using the number of subjects showing recombinations between RYR1 and MH susceptibility (table 1) and our current understanding of the molecular genetics of MH, it is possible to place these families into one of three categories. The first category includes the nine pedigrees where there is complete segregation between RYR1 and MH susceptibility, which is wholly consistent with linkage to RYR1 in these families. The second category, consisting of three pedigrees, is that in which there are at least two recombinants between RYR1 and MH susceptibility, suggesting that linkage to the RYRI is unlikely. The 
